Tim Schutte

He has been working at the Netherlands Cancer Institute since 2024 and specializes in treating patients in early clinical trials. In these studies, patients are treated with new experimental drugs. The goal of many of these studies is to find a safe and proper dosage. These new drugs are, for example, new forms of immunotherapy or targeted drugs against tumor proteins.

"I find my work inspiring because of the special conversations with patients I get to supervise, the ability to contribute to the development of new medicines, and the (international) collaboration with researchers from the lab, the hospital and pharmaceutical companies."

Currently, he is a member of the executive board of the NedMec (Medical Ethics Committee), a member of the Medical Oncology editorial board, and he works together within the phase 1 network of Cancer Core Europe.

Specialism and interests

• Early drug development and clinical trials
• Rare cancers
• Personalized Dosing and Therapeutic Drug Monitoring 
• Translational research into pharmacological concepts
• Mechanisms of drug resistance 

Publications

In the National Library of Medicine , you can view Tim Schutte's publications.

Relevant committees/networks/other relevant experience

• Cancer Core Europe Phase 1 network
• Member DPOG (Dutch Pharmacology Oncology Group)
• Member of the national platform for early phase clinical research 
• Executive Committee of NedMec (METc)
• Editorial Board Medical Oncology